Vytorin and Zetia may have hit bottom

Well, it's not good news for those long-suffering cholesterol meds Vytorin and Zetia--but at least it's not more bad news. The two drugs, which have seen new scrips fall and fall again since less-than-stellar research news first hit in January, may finally be bottoming out.

The latest sales report from Schering-Plough shows that prescriptions for the two meds actually took a tiny tick upward to $2.19 million in October from $2.17 million in September. That's way down from the $3 million-plus posted back in January, but the numbers could definitely be worse.

As you know, Schering and Merck together sell Vytorin, a combo of the Merck statin Zocor (generic simvastatin) and Zetia, another cholesterol fighter that works via a different mechanism. Since January, the Vytorin/Zetia franchise has sustained a series of blows, starting with the Enhance study, which suggested that Vytorin doesn't slow heart disease any better than Zocor would on its own. Another study suggested that Vytorin and Zetia might boost the risk of cancer, and though that data has been called anomalous by various experts, the continuing debate hasn't helped sales.

As the Wall Street Journal Health Blog notes, next month's scrip figures could be telling: If the numbers continue to hold their own, Vytorin and Zetia may finally have hit bottom.

- read the Health Blog post

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.